A detailed history of Walleye Capital LLC transactions in Arvinas, Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 1,800 shares of ARVN stock, worth $35,262. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,800
Previous 25,157 92.84%
Holding current value
$35,262
Previous $669,000 93.42%
% of portfolio
0.0%
Previous 0.0%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$23.66 - $32.73 $49,402 - $68,340
2,088 Added 8.3%
27,245 $671,000
Q2 2024

Aug 14, 2024

SELL
$24.46 - $40.4 $230,682 - $381,012
-9,431 Reduced 27.27%
25,157 $669,000
Q1 2024

May 15, 2024

BUY
$36.38 - $52.31 $857,585 - $1.23 Million
23,573 Added 214.01%
34,588 $1.43 Million
Q4 2023

Feb 14, 2024

BUY
$14.19 - $42.33 $156,302 - $466,264
11,015 New
11,015 $453,000
Q1 2023

May 15, 2023

BUY
$26.15 - $37.26 $429,566 - $612,070
16,427 New
16,427 $448,000
Q2 2022

Aug 08, 2022

BUY
$36.01 - $74.24 $2.23 Million - $4.6 Million
61,919 New
61,919 $2.61 Million
Q1 2022

May 16, 2022

SELL
$60.27 - $81.57 $955,038 - $1.29 Million
-15,846 Closed
0 $0
Q4 2021

Mar 03, 2022

BUY
$65.85 - $96.21 $1.04 Million - $1.52 Million
15,846 New
15,846 $1.3 Million

Others Institutions Holding ARVN

About ARVINAS, INC.


  • Ticker ARVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,205,300
  • Market Cap $1.04B
  • Description
  • Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...
More about ARVN
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.